Valeant (VRX) Would Not Be Selling Core Assets if All Was Well - Wells Fargo's Maris
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Valeant Pharma (VRX): Salix Sale Resolves Nothing - Mizuho
November 2, 2016 7:20 AM EDTMizuho Securities analyst, Irina Koffler, reiterated her Neutral rating on shares of Valeant Pharmaceuticals (NYSE: VRX) noting that the Salix sale resolves "nothing".
The analyst believes the financial impact will be nominal and the 33% increase overestimates the importance. No change to the... More
Valeant Pharma (VRX) Affirms Being in Discussions for Various Divestitures; May Include Salix Sale
November 1, 2016 5:37 PM EDTValeant Pharma (NYSE: VRX) issued the following statement regarding comments attributed to anonymous sources in a press report regarding its Gastroenterology business unit:
"In accordance with its duties to shareholders and other stakeholders, management evaluates any transaction relating to core or non-core... More
Valeant Pharma (VRX) in Advanced talks to Sell Salix to Takeda for $10B - DJ
November 1, 2016 3:36 PM EDT(Updated - November 1, 2016 3:39 PM EDT)
Valeant Pharma (NYSE: VRX) is in advanced talks to sell Salix to Takeda for $10 billion, according to Dow Jones, citing sources. Another unnamed bidder is said to be circling Salix.
A deal could be reached in the coming weeks.
... More
